Skip to main content
ADRX
NASDAQ Life Sciences

OrbiMed Buys $16.15M in ADARx IPO, Converts 23.3M Preferred Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$20.3
Mkt Cap
$1.503B
52W Low
$18.5
52W High
$23.21
52W Position info
9.7% above low
Off High info
13% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ADRX is trading near its 52-week low of $18.5 (9.7% above the low).

Summary

OrbiMed Advisors bought $16.15M of ADARx common stock at the $17.00 IPO price and converted 23.3M preferred shares into common stock upon the IPO closing.


Key Events · Ownership and Investor Activity · ADRX

  • OrbiMed Buys $16.15M at IPO Price

    OrbiMed Advisors purchased 950,000 shares at $17.00 per share for $16.15 million in ADARx's IPO, which closed September 28, 2026.

  • Preferred Conversion Adds 23.3M Shares

    OrbiMed converted 23,255,789 shares of Series A, B, B-1, and C preferred stock into common stock on a 1-for-1.1717 basis upon IPO closing.

  • Post-Transaction Holdings

    OrbiMed entities hold 14,325,529 shares indirectly across multiple funds, with Carl L. Gordon and Erez Chimovits serving on ADARx's board.

  • IPO Context

    Follows ADARx's $446.3 million upsized IPO and $89.3 million AbbVie private placement, both closed September 28, 2026.


Analysis · ADRX · Life Sciences

A major healthcare investment firm and 10% owner, OrbiMed Advisors, purchased 950,000 shares at the $17.00 IPO price for $16.15 million and converted 23.3 million preferred shares into common stock upon ADARx's IPO closing. This follows the $446 million upsized IPO and $89.3 million AbbVie private placement that closed September 28. OrbiMed's open-market purchase at the IPO price demonstrates conviction from a sophisticated life-sciences investor, while the preferred conversion adds significant common stock to the float.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADRX was trading at $20.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.50 to $23.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADRX - Latest Insights

ADRX
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $14.16 info
Change: -$0.750 (-5%) info
Market Cap: $1.574B info
ADRX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $14.16 info
Change: -$0.750 (-5%) info
Market Cap: $1.574B info
ADRX
Oct 01, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.57
Real-time Price: $14.16 info
Change: -$5.41 (-28%) info
Market Cap: $1.574B info
ADRX
Sep 29, 2026, 9:43 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $20.63
Real-time Price: $14.16 info
Change: -$6.47 (-31%) info
Market Cap: $1.574B info
ADRX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.09
Real-time Price: $14.16 info
Change: -$5.93 (-30%) info
Market Cap: $1.574B info